BioSight
Companies
Theravance Biopharma, Inc. logo

TBPH

NASDAQGEORGE TOWN, GRAND CAYMAN, CA
Theravance Biopharma, Inc.

Theravance Biopharma is a biopharmaceutical company focused on respiratory and neurological indications, with the FDA-approved small molecule YUPELRI (revefenacin) inhalation solution for maintenance treatment of chronic obstructive pulmonary disease and the clinical-stage small molecule ampreloxetine being developed for symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy, though the ampreloxetine Phase 3 CYPRESS study failed to meet its primary endpoint in March 2026 and the program is being wound down.

Price history not yet available for TBPH.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar